Knockdown of SLC7A5 inhibits malignant progression and attenuates oxaliplatin resistance in gastric cancer by suppressing glycolysis

Abstract Background Chemotherapy resistance is a major challenge in the treatment of intermediate and advanced gastric cancer (GC). This study aimed to recognize oxaliplatin resistance-related genes (OXARGs) in GC and to explore their role and mechanism in oxaliplatin resistance of GC. Methods OXARG...

Full description

Saved in:
Bibliographic Details
Main Authors: Yan Zhang, Jian Cao, Zheng Yuan, Jiahui Zhou, Hao Zuo, Xinsheng Miao, Xinhua Gu
Format: Article
Language:English
Published: BMC 2025-03-01
Series:Molecular Medicine
Subjects:
Online Access:https://doi.org/10.1186/s10020-025-01175-9
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849392133171052544
author Yan Zhang
Jian Cao
Zheng Yuan
Jiahui Zhou
Hao Zuo
Xinsheng Miao
Xinhua Gu
author_facet Yan Zhang
Jian Cao
Zheng Yuan
Jiahui Zhou
Hao Zuo
Xinsheng Miao
Xinhua Gu
author_sort Yan Zhang
collection DOAJ
description Abstract Background Chemotherapy resistance is a major challenge in the treatment of intermediate and advanced gastric cancer (GC). This study aimed to recognize oxaliplatin resistance-related genes (OXARGs) in GC and to explore their role and mechanism in oxaliplatin resistance of GC. Methods OXARGs with prognostic value in GC were analyzed using GC oxaliplatin resistance data from the GEO and TCGA databases. RT-qPCR and WB assay were applied to verify the expression of MT2A, NOTCH1 and SLC7A5 in oxaliplatin-resistant GC cells (HGC27R and MKN45R). The effect of SLC7A5 on the malignant phenotype of oxaliplatin-resistant GC cells was verified by CCK-8, EDU, TUNEL, colony formation, wound healing, transwell assay, tumor bearing experiments and WB assay. Results Bioinformatics analysis and experimental validation indicate that SLC7A5 was a target for oxaliplatin-resistance in GC. Knockdown of SLC7A5 obviously decreased the viability, migration, and invasion of oxaliplatin-resistant GC cells in vitro and tumor growth in vivo. It also increased the apoptosis levels and BAX expression, and reduced the expression of BCL2, MMP 2 and MMP9. Additionally, the knockdown of SLC7A5 enhanced the sensitivity of oxaliplatin-resistant GC cells to oxaliplatin both in vitro and in vivo. Furthermore, knockdown of SLC7A5 downregulated the expression of HK2, LDHA, Glut1, and PDK1 both in vivo and in vitro, leading to increased extracellular glucose levels and decreased lactate levels. However, glutathione significantly attenuated the regulatory effect of SLC7A5 knockdown on the malignant phenotype of oxaliplatin-resistant GC cells. Trial registration Not Applicable. Conclusion Knockdown of SLC7A5 inhibits malignant progression and attenuates oxaliplatin resistance in GC by suppressing glycolysis.
format Article
id doaj-art-d2de99d88592453d9f35b6d615c32c64
institution Kabale University
issn 1528-3658
language English
publishDate 2025-03-01
publisher BMC
record_format Article
series Molecular Medicine
spelling doaj-art-d2de99d88592453d9f35b6d615c32c642025-08-20T03:40:50ZengBMCMolecular Medicine1528-36582025-03-0131112210.1186/s10020-025-01175-9Knockdown of SLC7A5 inhibits malignant progression and attenuates oxaliplatin resistance in gastric cancer by suppressing glycolysisYan Zhang0Jian Cao1Zheng Yuan2Jiahui Zhou3Hao Zuo4Xinsheng Miao5Xinhua Gu6Department of Gastrointestinal Surgery, Suzhou Municipal Hospital, Suzhou Hospital Affiliated to Gusu School of Nanjing Medical UniversityDepartment of Gastroenterology, Suzhou Municipal Hospital, Suzhou Hospital Affiliated to Gusu School of Nanjing Medical UniversityDepartment of Gastrointestinal Surgery, Suzhou Municipal Hospital, Suzhou Hospital Affiliated to Gusu School of Nanjing Medical UniversityDepartment of Gastrointestinal Surgery, Suzhou Municipal Hospital, Suzhou Hospital Affiliated to Gusu School of Nanjing Medical UniversityDepartment of Gastrointestinal Surgery, Suzhou Municipal Hospital, Suzhou Hospital Affiliated to Gusu School of Nanjing Medical UniversityDepartment of Gastrointestinal Surgery, Suzhou Municipal Hospital, Suzhou Hospital Affiliated to Gusu School of Nanjing Medical UniversityDepartment of Gastrointestinal Surgery, Suzhou Municipal Hospital, Suzhou Hospital Affiliated to Gusu School of Nanjing Medical UniversityAbstract Background Chemotherapy resistance is a major challenge in the treatment of intermediate and advanced gastric cancer (GC). This study aimed to recognize oxaliplatin resistance-related genes (OXARGs) in GC and to explore their role and mechanism in oxaliplatin resistance of GC. Methods OXARGs with prognostic value in GC were analyzed using GC oxaliplatin resistance data from the GEO and TCGA databases. RT-qPCR and WB assay were applied to verify the expression of MT2A, NOTCH1 and SLC7A5 in oxaliplatin-resistant GC cells (HGC27R and MKN45R). The effect of SLC7A5 on the malignant phenotype of oxaliplatin-resistant GC cells was verified by CCK-8, EDU, TUNEL, colony formation, wound healing, transwell assay, tumor bearing experiments and WB assay. Results Bioinformatics analysis and experimental validation indicate that SLC7A5 was a target for oxaliplatin-resistance in GC. Knockdown of SLC7A5 obviously decreased the viability, migration, and invasion of oxaliplatin-resistant GC cells in vitro and tumor growth in vivo. It also increased the apoptosis levels and BAX expression, and reduced the expression of BCL2, MMP 2 and MMP9. Additionally, the knockdown of SLC7A5 enhanced the sensitivity of oxaliplatin-resistant GC cells to oxaliplatin both in vitro and in vivo. Furthermore, knockdown of SLC7A5 downregulated the expression of HK2, LDHA, Glut1, and PDK1 both in vivo and in vitro, leading to increased extracellular glucose levels and decreased lactate levels. However, glutathione significantly attenuated the regulatory effect of SLC7A5 knockdown on the malignant phenotype of oxaliplatin-resistant GC cells. Trial registration Not Applicable. Conclusion Knockdown of SLC7A5 inhibits malignant progression and attenuates oxaliplatin resistance in GC by suppressing glycolysis.https://doi.org/10.1186/s10020-025-01175-9Gastric cancerOxaliplatin resistanceSLC7A5GlycolysisBioinformatics
spellingShingle Yan Zhang
Jian Cao
Zheng Yuan
Jiahui Zhou
Hao Zuo
Xinsheng Miao
Xinhua Gu
Knockdown of SLC7A5 inhibits malignant progression and attenuates oxaliplatin resistance in gastric cancer by suppressing glycolysis
Molecular Medicine
Gastric cancer
Oxaliplatin resistance
SLC7A5
Glycolysis
Bioinformatics
title Knockdown of SLC7A5 inhibits malignant progression and attenuates oxaliplatin resistance in gastric cancer by suppressing glycolysis
title_full Knockdown of SLC7A5 inhibits malignant progression and attenuates oxaliplatin resistance in gastric cancer by suppressing glycolysis
title_fullStr Knockdown of SLC7A5 inhibits malignant progression and attenuates oxaliplatin resistance in gastric cancer by suppressing glycolysis
title_full_unstemmed Knockdown of SLC7A5 inhibits malignant progression and attenuates oxaliplatin resistance in gastric cancer by suppressing glycolysis
title_short Knockdown of SLC7A5 inhibits malignant progression and attenuates oxaliplatin resistance in gastric cancer by suppressing glycolysis
title_sort knockdown of slc7a5 inhibits malignant progression and attenuates oxaliplatin resistance in gastric cancer by suppressing glycolysis
topic Gastric cancer
Oxaliplatin resistance
SLC7A5
Glycolysis
Bioinformatics
url https://doi.org/10.1186/s10020-025-01175-9
work_keys_str_mv AT yanzhang knockdownofslc7a5inhibitsmalignantprogressionandattenuatesoxaliplatinresistanceingastriccancerbysuppressingglycolysis
AT jiancao knockdownofslc7a5inhibitsmalignantprogressionandattenuatesoxaliplatinresistanceingastriccancerbysuppressingglycolysis
AT zhengyuan knockdownofslc7a5inhibitsmalignantprogressionandattenuatesoxaliplatinresistanceingastriccancerbysuppressingglycolysis
AT jiahuizhou knockdownofslc7a5inhibitsmalignantprogressionandattenuatesoxaliplatinresistanceingastriccancerbysuppressingglycolysis
AT haozuo knockdownofslc7a5inhibitsmalignantprogressionandattenuatesoxaliplatinresistanceingastriccancerbysuppressingglycolysis
AT xinshengmiao knockdownofslc7a5inhibitsmalignantprogressionandattenuatesoxaliplatinresistanceingastriccancerbysuppressingglycolysis
AT xinhuagu knockdownofslc7a5inhibitsmalignantprogressionandattenuatesoxaliplatinresistanceingastriccancerbysuppressingglycolysis